DEF: Doximity Reports Strong Fiscal 2025 Performance, Proposes Director Re-election Amidst Ongoing Litigation

Doximity, Inc. announced its fiscal year 2025 results, revealing revenue and adjusted EBITDA exceeding targets, while also detailing proposals for its upcoming Annual Meeting of Stockholders and disclosing ongoing securities and derivative lawsuits.

Summary

• Doximity, Inc. will hold its Annual Meeting of Stockholders for fiscal year 2025 virtually on August 28, 2025, at 9:00 a.m. Pacific Time.
• Stockholders of record as of July 3, 2025, are entitled to vote on proposals including the re-election of two Class I directors, ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation.
• The company reported fiscal year 2025 consolidated revenue exceeding $570 million and adjusted EBITDA exceeding $250 million, surpassing internal targets.
• CEO Jeff Tangney's base salary increased by 100% from $300,000 to $600,000, retroactively effective April 1, 2024.
• Mr. Tangney earned a maximum 200% payout for his fiscal year 2025 cash incentive award, totaling $1,200,000, and 168,154 performance-based restricted stock units (PSUs) due to exceeding revenue and adjusted EBITDA goals.
• Other Named Executive Officers (NEOs) also received maximum achievement (110%) for the first step of their cash incentive awards due to strong financial performance.
• The CEO Pay Ratio for fiscal year 2025 was approximately 75 times, with the CEO's total compensation at $17,234,989 and the median employee's at $229,289.
• The company is currently involved in securities litigation and shareholder derivative lawsuits in the U.S. District Court for the Northern District of California and the District of Delaware, alleging securities law violations, breach of fiduciary duties, and other claims related to user count and engagement rates.
• Doximity emphasizes its commitment to Environmental, Social, and Governance (ESG) initiatives, including promoting equitable healthcare access through telehealth, fostering a diverse and inclusive workplace, and reducing its environmental footprint through cloud-based operations and remote work.
• The company's telehealth solution, Dialer, is estimated to avoid 3,000 to 3,500 metric tons of carbon dioxide equivalent emissions for every million virtual visits that replace car travel.
• The audit committee has re-appointed Deloitte & Touche LLP as the independent registered public accounting firm for the year ending March 31, 2026, with audit fees totaling $2,825,439 in fiscal year 2025.
• The company's insider trading policy prohibits hedging and pledging of Doximity stock, with a one-time exception granted to CEO Jeff Tangney in November 2023 for a loan, which was terminated in May 2025.
• A Clawback Policy was adopted on October 26, 2023, allowing recovery of erroneously awarded incentive-based compensation from executive officers in the event of an accounting restatement.

Sentiment

Score: 7

Explanation: The document highlights strong financial performance with revenue and adjusted EBITDA exceeding targets, leading to maximum executive incentive payouts. It also details robust corporate governance and significant ESG initiatives, particularly in reducing carbon footprint through telehealth. However, the disclosure of ongoing securities and derivative lawsuits, alleging issues with user count and engagement rates, introduces a notable negative risk factor that tempers the overall positive financial and governance news.

Positives

• Consolidated revenue for fiscal year 2025 exceeded $570 million, surpassing the target of $512 million.
• Adjusted EBITDA for fiscal year 2025 exceeded $250 million, surpassing the target of $244 million.
• CEO Jeff Tangney and other NEOs achieved maximum payouts for their fiscal year 2025 incentive compensation due to strong financial performance.
• The company received strong stockholder support for its executive compensation program, with approximately 98.6% of votes in favor at the 2024 annual meeting.
• Doximity maintains robust corporate governance practices, including an independent board majority and independent audit, compensation, and nominating & governance committees.
• The company actively manages ESG issues, focusing on equitable healthcare, employee well-being, diversity, equity, inclusion, and belonging (DEIB), and environmental responsibility.
• Telehealth tools like Dialer contribute to significant greenhouse gas emission reductions, estimated at 3,000 to 3,500 metric tons of CO2e per million virtual visits.
• The company's digital tools, including newsfeed, network tools, careers tools, and communication/workflow tools (telehealth, digital fax, secure messaging, AI writing assistant, scheduling), enhance physician productivity and patient care in a HIPAA-compliant environment.
• A comprehensive bug bounty program and dedicated security team ensure high data security standards, with all data encrypted in transit and at rest.

Negatives

• The company and certain directors/officers are named in ongoing securities litigation and shareholder derivative lawsuits, alleging securities law claims, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste.
• The lawsuits relate to disclosures of user count and engagement rates, indicating potential issues with reported operational metrics.

Risks

• Ongoing securities litigation and shareholder derivative lawsuits could result in significant financial liabilities, reputational damage, and diversion of management attention.
• The outcome of legal proceedings is uncertain, and adverse judgments could materially impact the company's financial condition and operations.
• The company's ability to attract and retain top talent in a highly competitive industry and geographic region is a continuous challenge, despite competitive compensation programs.
• Reliance on third-party service providers for certain functions (e.g., Broadridge for proxy materials) introduces operational risks.
• The company's business model is subject to regulatory changes, particularly those related to healthcare, data privacy (HIPAA), and securities laws.

Future Outlook

The company's executive compensation program is designed to evolve with business needs, focusing on long-term incentives to align executive interests with stockholder value creation. The board will continue to consider stockholder feedback from the annual Say-on-Pay vote when making future compensation decisions. The company also plans to continue assessing its environmental impact and seeking innovative ways to build a more sustainable business as it grows.

Management Comments

• "We are pleased to invite you to attend the Annual Meeting of Stockholders..."
• "Thank you for your ongoing support of Doximity."
• "Our board of directors recommends that you vote FOR the director nominees named in Proposal One, FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm as described in Proposal Two, and FOR the Say-on-Pay Proposal."
• "We believe Mr. Tangney is qualified to serve as a member of our board of directors because of the perspective and experience he brings as our Chief Executive Officer."
• "We believe Ms. Wampler is qualified to serve on our board of directors because of her extensive experience advising technology companies as both a director and executive."
• "We believe Dr. Benjamin is qualified to serve on our board of directors because of her extensive experience in both business and practice as a medical doctor and her experience advising other public companies."
• "We believe Ms. Yang is qualified to serve on our board of directors because of her extensive industry experience as both a director and executive."
• "We believe Mr. Cabral is qualified to serve on our board of directors because of his experience as an executive and director of a public company."
• "We believe Mr. Spain is qualified to serve on our board of directors because of his extensive industry experience and his experience advising other public companies."
• "Our board and management team are committed to good corporate governance to ensure that we are managed for the long-term benefit of our stockholders."
• "We believe that our compensation plans, policies and awards, balance an appropriate risk and reward profile in relation to our overall business strategy and do not encourage our employees, including our executive officers, to engage in risk taking to a degree that is reasonably likely to have a materially adverse impact on us or our operations."
• "We believe that our NEO compensation program is competitive within our industry and strongly aligned with the long-term interests of our stockholders."
• "The defendants intend to defend vigorously against these actions."

Industry Context

Doximity operates in the highly competitive healthcare technology and application software sectors, serving U.S. medical professionals. Its focus on digital tools for physicians aligns with broader industry trends towards digital transformation in healthcare, aiming to improve productivity and patient care. The company's emphasis on HIPAA compliance and data security is critical in a sector dealing with sensitive patient information. Its peer group for compensation analysis includes other high-growth companies in application software and healthcare technology, reflecting the competitive landscape for talent and market positioning.

Comparison to Industry Standards

• Doximity's executive compensation practices are benchmarked against a peer group of 21 companies, including Alteryx, GoodRx, AppFolio, Guardant Health, Asana, HashiCorp, Bill.com, nCino, C3.ai, PagerDuty, Certara, Phreesia, Clearwater Analytics Holdings, Procore Technologies, Confluent, Samsara Inc., Dynatrace, Schrdinger, LLC, Elasticsearch, Smartsheet Inc., and EngageSmart, Inc., selected based on sector, revenue ($225M-$1.2B), market capitalization ($1.5B-$13B), and headcount (300-3,000 employees).
• The company's cumulative Total Shareholder Return (TSR) is compared against the weighted peer group TSR of the S&P 500 Information Technology Index, indicating its performance relative to a broad industry benchmark.
• The CEO's base salary increase to $600,000 and overall compensation structure are stated to be better aligned with peer market data for a chief executive role in a competitive market.
• The company's commitment to data security, including TLS 1.2 encryption, AES-256 encryption for personal health information, Web Application Firewall, Runtime Application Self-Protection, Bot Protection, Rate-Limiting, and DDoS mitigation technology, aligns with or exceeds standard industry practices for healthcare technology platforms handling sensitive data.
• The estimated avoidance of 3,000 to 3,500 metric tons of carbon dioxide equivalent emissions per million virtual visits through its telehealth platform demonstrates a significant environmental benefit compared to traditional in-person care models, contributing positively to industry-wide sustainability efforts.

Management Changes

Corporate Governance

Legal Proceedings

• In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02281 (N.D. Cal.): Securities law claims against the company and CEO related to disclosure of user count and engagement rates, currently in the discovery phase.
• In re Doximity, Inc. Stockholder Derivative Litigation, No. 5:24-cv-02801 (N.D. Cal.): Consolidated shareholder derivative lawsuits asserting claims for violations of securities law, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain directors and officers.
• Guttman v. Tangney, et al,. 1:24-cv-01387 (D. Del): A third derivative lawsuit with similar claims against certain directors and officers.
• The defendants intend to defend vigorously against all these actions.

Related Party Transactions

• The company is party to an investors rights agreement with Jeff Tangney (CEO), entities affiliated with Mr. Tangney, InterWest Partners, Emergence Capital Partners, and Morgenthaler Ventures, which provides certain holders with registration rights for their capital stock.
• A one-time exception to the insider trading policy was granted in November 2023 to CEO Jeff Tangney to secure a loan with a third-party financial institution using certain shares of Doximity Class A common stock as collateral (less than 5% of his overall equity ownership). This loan was terminated in May 2025, and the subject shares were released as collateral.

Stakeholder Impact

• Shareholders: Will vote on key governance matters, including director elections and executive compensation. The strong financial performance and executive compensation structure are designed to align with shareholder interests and long-term value creation. However, ongoing legal proceedings pose a risk to shareholder value.
• Employees: Benefit from competitive compensation, equity stock incentives, an employee stock purchase plan, bonus opportunities, 401(k) with employer match, high-quality medical/dental benefits, family planning benefits, and a monthly well-being stipend. The company fosters a culture of 'straight talk' and DEIB initiatives.
• Customers (pharmaceutical manufacturers and health systems): Benefit from broad physician usage of the platform and access to commercial solutions for marketing, hiring, and productivity.
• Physicians/Medical Professionals (Members): Provided with digital tools to enhance productivity, facilitate clinical collaboration, stay updated on medical news, manage careers, streamline administrative tasks, and conduct virtual patient visits in a HIPAA-compliant environment.
• Creditors: The termination of the loan secured by CEO Jeff Tangney's shares indicates a reduction in personal leverage, which could be viewed positively, though the company's overall financial health is the primary concern for creditors.
• Regulatory Authorities: The company's adherence to SEC rules (e.g., Say-on-Pay, Section 16(a) reporting, Clawback Policy) and commitment to HIPAA compliance are critical for maintaining regulatory standing.

Next Steps

• Hold the Annual Meeting of Stockholders on August 28, 2025, to vote on director elections, auditor ratification, and executive compensation.
• Continue to defend vigorously against the ongoing securities litigation and shareholder derivative lawsuits.
• The board and compensation committee will consider the outcome of the Say-on-Pay vote when making future executive compensation decisions.
• The company will continue to assess its environmental impact and search for innovative ways to build a more sustainable business.
• File a Current Report on Form 8-K within four business days after the Annual Meeting to announce preliminary or final voting results.

Key Dates

Recommendation

Keywords

Doximity, SEC Filing, Proxy Statement, Annual Meeting, Executive Compensation, Corporate Governance, Financial Performance, Revenue, Adjusted EBITDA, Legal Proceedings, Securities Litigation, Shareholder Derivative Lawsuit, ESG, Telehealth, Healthcare Technology, Physician Network, Stockholder Vote, Director Election, Auditor Ratification, Say-on-Pay, Class A Common Stock, Class B Common Stock, RSUs, PSUs, CEO Pay Ratio, Clawback Policy, Insider Trading Policy, GHG Emissions